The Janssen Pharmaceutical Companies of Johnson & Johnson received FDA approval for Xarelto (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). Xarelto is now the first and only Factor Xa inhibitor approved for patients living with…
A Single Dose of Janssen ‘s Stelara Induces Clinical Remission of Ulcerative Colitis
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data showing treatment with a single intravenous (IV) dose of Stelara (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously experienced an inadequate response or were intolerant to conventional or biologic therapies. Results from the induction phase of…
Janssen’s Tremfya Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new data that show considerable improvements in long-term patient-reported outcomes (PRO) in patients switched to Tremfya (guselkumab) after an initial inadequate response to adalimumab.1 In addition, PRO measurement tools such as the Psoriasis Symptom and Sign Diary (PSSD) may provide a more accurate representation of the impact…
FDA Approves Imbruvica Plus Rituximab for Rare Blood Cancer
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia (WM), a rare blood cancer.1 The approval expands the label for Imbruvica in WM beyond its current approved use as a monotherapy to include combination use with rituximab. This approval represents the…
Janssen Reports Positive Topline Results for Novel HIV-1 Phase III Study
Janssen confirmed positive topline results from the global, Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study of the first investigational long-acting injectable two-drug regimen (2DR) for the treatment of HIV-1. The ATLAS study results showed long-acting rilpivirine (Janssen Sciences Ireland UC) and cabotegravir (ViiV Healthcare), injected once a month, had similar efficacy to a…